Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

Learn more about:
Related Clinical Trial
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor International Pediatric Adrenocortical Tumor Registry Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Structured Evaluation of adRENal Tumors Discovered Incidentally – Prospectively Investigating the Testing Yield Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Possible New Therapy for Advanced Cancer IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Studying Genes in Samples From Younger Patients With Adrenocortical Tumor Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Evaluation of Side Effects of Mitotane Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Sunitinib in Refractory Adrenocortical Carcinoma Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Cabozantinib in Advanced Adrenocortical Carcinoma Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma German Adrenocortical Carcinoma Registry Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Brief Title

Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

Brief Summary

      The improvement of conventional imaging techniques has led to an increased detection rate of
      different adrenal tumors. Since those tumors can belong to a variety of entities the
      therapeutic consequences also show considerable variation. In order to definitely determine
      the type of tumor, invasive procedures like CT guided biopsies are often required, which
      could be avoided by a tumor specific imaging method. The presently available scintigraphic
      procedures are either time consuming and lead to high radiation exposure or are technically
      demanding. The steroidogenic enzymes CYP11B1 (11ß-hydroxylase)and CYP11B2 (aldosterone
      synthase)are expressed exclusively in the adrenal cortex and therefore represent suitable
      targets for a specific imaging technique. In our project we evaluate 123I-Iodometomidate
      which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.

Study Phase

Phase 1/Phase 2

Study Type



Adrenal Tumor




* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Start Date

March 2007

Completion Date

February 2009

Primary Completion Date

December 2008

Eligibility Criteria

        Inclusion Criteria:

          1. Adrenal tumor seen by CT or MRT-scan with diameter of at least 2 cm or patient with
             adrenocortical carcinoma and suspected metastasis or local recurrence or patients with
             primary hyperaldosteronismus and adrenal tumour > 1 cm

          2. Hormonal work up of of the adrenal tumor according to [email protected] (European network for the
             study of adrenal tumours)-criteria

          3. Age ≥ 30 Jahre

          4. Effective contraception (pearl index <1%)

          5. Written informed consent

        Exclusion Criteria:

          1. Pregnancy or breast feeding

          2. Renal insufficiency (serum creatinine > 2,0 mg/dl or MDRD < 60 ml/min)

          3. Known allergy to etomidate or constituents of the test drug




30 Years - N/A

Accepts Healthy Volunteers



Christoph Reiners, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

University of Wuerzburg

Study Sponsor

Christoph Reiners, MD, Principal Investigator, University of Wuerzburg

Verification Date

October 2007